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Abstract
With the purpose to improve the biological activities of curcumin, eight novel ferrocenyl curcuminoids were synthesized by covalent
anchorage of three different ferrocenyl ligands. We evaluated their cytotoxicity on B16 melanoma cells and normal NIH 3T3 cells,
their inhibition of tubulin polymerization and their effect on the morphology of endothelial cells. The presence of a ferrocenyl side
chain was clearly shown to improve the biological activity of most of their corresponding organic curcuminoid analogues.
Author Keywords curcuminoid ; ferrocenyl ; B16 melanoma ; NIH 3T3 cells ; endothelial cells ; cancer
Curcumin (Figure 1), the major constituent of the rhizome , is a yellow pigment of the spice turmeric. This non-toxic1 Curcuma Longa
1  dietary phytomolecule has been used for centuries in Asia for its medicinal properties, and regained considerable attention recently due[ ]
to its several health promoting effects, such as antioxidant, 2,3  anti-inflammatory, 4  chemopreventive, 5 7  and antitumor activities on[ ] [ ] [ – ]
several cancer types. 8,9  The precise mechanism of action of curcumin in cancer cells is still not completely understood and appears to be[ ]
mediated by several different pathways. For example, curcumin was reported to induce apoptosis by suppression of nuclear factor- Bκ
described in several cancer cell lines such as melanoma. 10  Curcumin was also reported to interact with tubulin polymerization, although[ ]
these data are considered controversial because high concentrations are needed for inhibition. 11 13[ – ]
Great interest has been devoted to the synthesis of new curcumin analogues exhibiting enhanced biological properties. For example,
dimethylcurcumin (Figure 1), is more effective at inhibiting colon cancer cell proliferation  14  and is metabolically more stable.2 in vitro [ ] [
15  Another interesting strategy has been to chelate a metal to curcumin in order to increase the cytotoxicity of the parent molecule.]
Indeed, the use of metal-based compounds for the treatment of cancer has found significant interest in medicine 16  (e.g., clinical use of[ ]
cisplatinum compounds), thus encouraging chemists to design new metallated anticancer agents. Several examples of metallated
curcuminoid analogues, which all involve the coordination of the metal to the oxygens of the -diketone, have been evaluated for theirβ
biological properties. 17 25  Because there were no published reports of an organometallic moiety covalently grafted to curcumin or its[ – ]
derivatives, we recently described the synthesis of the first examples of such ferrocenyl derivatives , and (Figure 1). 26  We therefore5 6 7 [ ]
became interested to further investigate the covalent anchorage of a ferrocenyl unit to several curcuminoids. We hypothesized that the
presence of ferrocene in curcumin derivatives could enhance the biological activity against cancer cells, as we previously reported for
ferrocenyl derivatives of steroidal antiandrogens 27  and of the antioestrogen tamoxifen. 28,29[ ] [ ]
In the present report, we synthesized eight novel ferrocenyl curcuminoids in order to evaluate some of their biological properties. To
do so, three different ferrocenyl spacer chains were chosen to be anchored to the central carbon of the curcuminoid skeleton: ferrocenyl
propenone to increase the conjugation up to the ferrocenyl (series A), ferrocenyl methylene forcing the -diketone to be in its diketoneβ
tautomer form (series B), and ferrocenyl ethanone interrupting the conjugation between the skeleton and the ferrocenyl moiety (series C).
The effect of the substitution by a methoxyl instead of an hydroxyl on the two phenyl groups was also investigated by choosing
dimethylcurcumin , 3,5-dimethoxycurcumin and trimethoxycurcumin (Figure 1) as curcuminoid skeleton, in addition to curcumin.2 3 4 
Although and have already been reported in the literature, 30  they have not been studied in details.3 4 [ ]
We report here the synthesis of several ferrocenyl derivatives of the curcuminoids , , and . We also tested these ferrocenyl1 2 3 4 
derivatives for some important biological activities required for anticancer activity, i.e., their cytotoxicity against murine B16 melanoma
cells and NIH 3T3 normal cells, their effect on the inhibition of tubulin polymerization and the analysis of the morphological effects on
endothelial cells (as a model of antitumor antivascular effect). 31  For comparison purposes, curcumin and compounds , and also[ ] 2 3 4 
underwent these biological tests.
Synthesis of curcuminoid ferrocenyl derivatives
The curcuminoids , , and (Figure 1) were synthesized following Pederson s conditions 32  by condensing an appropriate1 2 3 4 ’ [ ]
aldehyde with 2,4-pentanedione in the presence of a base as well as tributylborate and boric anhydride. The latter is required to complex
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the 2,4-dione moiety in order to prevent a Knoevenagel condensation on C-3. It was shown that the -diketone of curcumin exists asβ
keto-enol tautomer in solid state, 33  as well as in solution, 34  as observed for the three other curcuminoids ( , and ).[ ] [ ] 2 3 4 
We previously reported the synthesis of compound bearing a ferrocenyl propenone moiety (Scheme 1), obtained from5 
3,5-dimethoxycurcumin . 26  Following the same procedure, dimethylcurcumin and trimethoxycurcumin analogues and were also3 [ ] 8 9 
successfully synthesized. The enol of and was deprotonated by stirring in the presence of sodium hydride for 2 hours at room2 4 
temperature. Ferrocenyl propynone 35  was then added to produce and with yields of 25 and 14 , respectively. The rather modest[ ] 8 9 %
yields obtained, also observed previously for were explained by the degradation of the starting material if the reaction time was5 
prolonged. H NMR spectra of and were similar to that of and showed that the peak at 5.85 ppm, corresponding to the central proton1 8 9 5 
of the -diketone in its keto-enol form, had disappeared and confirmed that the substitution took place at the desired C-4 position. Theβ
crystal structure of has previously been reported. 265 [ ]
In order to force the -diketone of the curcuminoid to stay in its diketo form instead of the keto-enol form, the organic curcuminoids β 1 
, , and underwent a Knoevenagel condensation with ferrocenecarboxaldehyde to form , , and , respectively, following a2 3 4 10 11 12 13 
modified procedure reported for the substitution of organic species (Scheme 2). 36  In our case, ferrocenecarboxaldehyde was condensed[ ]
to the corresponding organic curcuminoid in the presence of freshly distilled piperidine in anhydrous DMF instead of a CHCl /EtOH3 
solution, in order to increase the yields of the newly formed ferrocenyl curcuminoids, e.g., from 3  to 27  for . Again, moderate yields% % 11 
(22 28 ) were obtained because of degradation with longer reaction times. Confirmation of the desired substitution was obtained by H– % 1 
NMR, as the peak of the central proton disappeared and the diketo form of the -diketone was confirmed by the appearance of a secondβ
carbonyl peak on the C NMR spectrum. It is noteworthy that these conditions of Knoevenagel condensation did not require prior13 
protection of the phenol groups of curcumin, therefore enabling us to prepare in one step.10 
With the purpose of studying the effect of an interruption of the conjugation between the curcuminoid and the ferrocenyl, a ferrocenyl
ethanone moiety was therefore grafted to dimethylcurcumin and a protected curcumin, (Scheme 3). Indeed, for this reaction, it was2 14 
necessary to protect the phenols of curcumin. We previously described a modified synthesis of a bis-tetrahydropyran ( ) and bis-14 t
-butyldimethylsilyl curcumin 26  and discussed the relative stability of ferrocenyl protected curcumin towards the different conditions of[ ]
deprotection for a THP and a TBDMS group. For this reaction, the protection by a THP moiety was chosen because deprotection occurs in
milder conditions than for TBDMS. Compounds and were deprotonated by sodium hydride in the same conditions as described2 14 
above, before -bromoacetylferrocene 37  (obtained from ferrocene and 2-bromoacetyl bromide) was added dropwise. After heating for 4α [ ]
hours and then stirring overnight at room temperature, and were formed in approximately 50  yield. The reaction has also been15 16 %
carried out using -chloroacetylferrocene, but was obtained in only 17  yield while could not be formed. The NMR spectra of α 15 % 16 15 
and showed that the -diketones were in their diketo- rather that their keto-enol forms. Indeed, in their H NMR spectra, the H-4 singlet16 β 1 
of the keto-enol form at 5.85 ppm disappeared, while a triplet at 4.95 ppm was observed, attributed to the H-4 of the diketo form.
Additionally, one peak at 195 ppm, corresponding to the two symmetrical carbonyl groups of the curcuminoid skeleton, was observed in
their C NMR spectra. Similar observations were reported by Pederson for the synthesis of several substituted organic curcuminoids. 3213 [ ]
For example, the synthesis consisting in the alkylation of curcumin on the central carbon (C-4) with benzyl bromide only led to the
tautomer in its diketo form.
In order to obtain the curcumin ferrocenyl ethanone derivative, the deprotection of the THP protecting groups of was carried out by16 
using pyridinium -toluenesulfonate (PPTS) in CH Cl /EtOH to lead to the formation of the desired unprotected ferrocenyl curcumin p 2 2 17 
in 68  yield, confirming the stability of ferrocenyl ethanone curcuminoids under mild acidic conditions. The NMR spectra of showed% 17 
that the -diketone is in the same diketo form as for the protected derivative .β 16 
Biological evaluation of the ferrocenyl derivatives of curcumin
The synthesized ferrocenyl curcuminoid derivatives were evaluated  for some biological properties frequently linked toin vitro
anticancer activity, i.e., for their cytotoxicity against murine B16 melanoma cells and NIH 3T3 normal cells, their effect on tubulin
polymerization, and their induction of a rapid morphological change of endothelial cells (rounding up) that may hint to a possible
antivascular effect. For comparison purposes, the organic compounds , , and were also tested in parallel, as well as combretastatin1 2 3 4 
A4 ( ), a well-known vascular disrupting agent. 38CA-4 [ ]
Cytotoxicity
The murine B16 melanoma cells were chosen to evaluate the cytotoxicity because melanoma is particularly refractory to
chemotherapy. Table 1 presents the cytotoxicity values (IC ) of the parent compound curcumin and its analogues. Curcumin showed an50 
IC value of 8.5 M, which is comprised within the literature values obtained for this cell line. For example, B16-BL6 melanoma 3950 μ [ ]
(highly metastatic) and B16-R melanoma 40  (resistant to doxorubicin) presented IC values of 3.6 and 18 M, respectively for a similar[ ] 50 μ
48 hour incubation time.
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Of the three organic curcuminoids evaluated for the first time in this study on B16 cells, it was of interest to note that
trimethoxycurcumin exhibited higher cytotoxic activity (IC  2.8 M) compared to , and (IC values comprised between 8.5 and4 50 = μ 1 2 3 50 
12.0 M). Looking at the substitution of the aromatic rings, it appears that the absence of substituent at the  position decreasesμ para
somewhat the cytotoxic activity of the resulting curcuminoid, because 3,5-dimethoxycurcumin showed the least cytotoxic effect with an3 
IC value of 12.0 M.50 μ
The two ferrocenyl unsymmetrical compounds and , as well as the ones of the series A ( , , and ), were shown to be weakly6 7 5 8 9 
cytotoxic. However, the four ferrocenyl derivatives of series B (containing a ferrocenyl methylene chain) presented the most cytotoxic
activity of our compounds with IC values ranging from 2.2 M for to 7.1 M for . For the dimethylcurcumin and50 μ 13 μ 11 
trimethoxycurcumin analogues ( and ), the ferrocenylation did not significantly improve the cytotoxic activity. However, we11 13 
observed an interesting two-fold increase in cytotoxicity for the ferrocenyl analogues of and , i.e., and . Representative curves1 3 10 12 
showing the decrease in number of viable cells upon treatment with increasing concentrations of the organic 3,5-dimethoxycurcumin and3 
its ferrocenyl analogue is depicted in Figure 2.12 
As a result, in the B16 cellular model, the diketo form of the ferrocenyl derivatives, as well as conjugation up to the ferrocenyl (series
B), seemed required for high cytotoxic activity. In series C, and , which are also in diketo form, but have disrupted conjugation, did15 17 
not exhibit increased cytotoxicity compared to their corresponding organic curcuminoids. Indeed, similar IC values were obtained for 50 15 
and dimethylcurcumin , while the cytotoxic activity of decreased dramatically compared to curcumin (75.7  8.5 M, respectively).2 17 1 vs μ
Although not in the same chemical series, our compounds were compared to combretastatin A4 which is considered as a standard
antivascular agent. All the curcuminoid analogues were less cytotoxic to B16 melanoma cells compared to combretastatin A4. For
example, the best cytotoxic curcuminoid analogue (IC 2.2 M) was about 700-fold less cytotoxic compared to combretastatin A4 (IC13 50 = μ
0.003 M)50 = μ
For comparison purposes, we also evaluated the cytotoxic activity of these compounds against the NIH 3T3 normal cell line. Table 1
shows that the IC of the normal cells were higher than the IC for the cancer cells (B16 melanoma) for most compounds (with the50 50 
exception of ). This could indicate an interesting selectivity of cytotoxic action against cancer cells compared to normal ones, as17 
previously observed for other curcuminoids (reviewed in reference 40-b).
Inhibition of tubulin polymerization (ITP)
We were also interested to test our curcumin ferrocenyl derivatives on tubulin polymerization, because several potent clinically used
anticancer drugs are indeed known to act on tubulin dynamics 41,42  (e.g., vinca alkaloids, taxanes), and because it was recently reported[ ]
that curcumin could also inhibit microtubule assembly. 11[ ]
In our assay conditions, curcumin was shown to inhibit microtubule formation with an IC value of 17.9 M (Table 1). Our data50 μ
corroborate Gupta and coworkers  observations, although their reported IC value is higher than ours (calculated IC  80 M). 11  A’ 50 50 ≈ μ [ ]
plausible explanation for our lower IC value is likely due, in our case, to a preincubation period of 45 minutes at room temperature in50 
presence of the tested compound, which allows for the tested ligand to more closely interact with tubulin prior to the beginning of the
polymerization with the addition of guanosine triphosphate (GTP) and incubation at 37 C. The function of this preincubation step is to°
maximize the potential for detecting the interaction of drugs with tubulin, and to give a better idea of the relative potency of slow-binding
agents (such as colchicinoids), both in comparison with each other, and in comparison with other classes of drugs. 43  Of the organic[ ]
curcuminoids, only curcumin presented an IC value of less that 30 M.50 μ
Within the series of the ferrocenyl curcuminoids, the unsymmetrical compound was not markedly active on tubulin polymerization,6 
whereas its isomer presented an IC value of 9.3 M.7 50 μ
Although the high activity of combretastatin could not be reached by the symmetrical organometallic compounds, the presenceCA-4 
of a ferrocenyl moiety was generally linked to a marked increase in tubulin inhibition activity compared to their organic counterparts, with
the exception of curcumin substituted with ferrocenyl methylene moiety , which showed a similar ITP activity.10 
The lowest IC values (2.1 to 5.8 M) were observed with the ferrocenyl propenone curcuminoids (series A). Compounds of series B50 μ
and C were all good tubulin polymerization inhibitor with concentrations comprised between 3.6 and 12.6 M, with still the exception ofμ
the curcumin analogue . By examining the substituents on phenyl rings, it was observed that the 3,4-dimethoxyl substitution of the10 
ferrocenyl curcuminoids (dimethylcurcumin derivatives , and ) produced the best antitubulin activity (2.5  5.5 M), whatever the8 11 15 – μ
spacer chain used.
Morphological effects on endothelial cells
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Because several antitumor antivascular compounds act on endothelial cells, we also tested the morphological effects of our novel
ferrocenyl compounds on immortalized HUVEC (Ea.hy 926), as a model of potential antitumor antivascular effect. 31,38[ ]
A rounding up effect of endothelial cells was observed only at high concentrations (50 100 M) for the organic curcuminoids (Table– μ
1). The introduction of the ferrocenyl allowed the morphological rounding up to occur at significantly lower concentrations for all series A,
B and C. In the series A, the concentration needed for rounding up was 12.5 M. For series B, with the exception of the dimethylcurcumin μ
and 3,5-dimethoxycurcumin analogues ( and ), a significant decrease in the concentration needed for rounding up of endothelial2 3 11 12 
cells was noted, as well as in series C (25 M).μ
These data clearly indicate that the presence of a ferrocenyl moiety could significantly lower the concentration needed for the rounding
up of endothelial cells for the majority of our symmetrical ferrocenyl curcuminoids. Figure 3 shows a representative change in endothelial
cells shape for compound (series B) at 6.3 M.13 μ
In addition, the increase in morphological activity of these curcuminoid analogues appeared to be correlated with their antitubulin
activity. As a matter of fact, we observed a statistically significant linear correlation between the ITP values (x) and the concentration
needed for rounding up (y), indicating that the best ITP values were linked to a lower concentration for morphological activity (y 1.81x= +
13.71, R 0.661, P<0.007).=
Conclusion
In this work, eight novel ferrocenyl curcuminoids were synthesized by covalent anchorage of three different ferrocenyl ligands to
organic curcuminoids substituted with methoxyl and hydroxyl groups on the aromatic rings. The presence of a ferrocenyl unit clearly
improved the biological activity of most novel ferrocenylated curcuminoids. Furthermore, this first study of organometallic moiety
covalently grafted to curcuminoids demonstrated the influence of the spacer chain between the curcuminoid skeleton and the ferrocenyl
unit on the resulting biological activity. Indeed the curcuminoids bearing the methylene linker exhibited the best cytotoxicity on murine
B16 cells (IC  2.2 7.1 M), whereas the presence of the propenone spacer chain induced the best tubulin polymerization inhibition and50 = – μ
rounding up of endothelial cells to occur at lower concentrations. Collectively, our results validate the strategy of covalently anchoring an
organometallic moiety to a curcuminoid in order to improve its biological activities.
Footnotes:
Numbering scheme for NMR assignment of curcuminoids skeleton. Experimental procedure andSupporting Information Available: 
characterization of compounds and . HRMS purity data of compounds - and - and elemental analyses of compounds 8-13 15-17 8 10 15 17 
and . Evaluation of cytotoxicity in murine B16 melanoma cells, inhibition of tubulin polymerization (ITP) and effect on the8-13 15-17 
morphology of transformed HUVEC cells (EA.hy 926 cells). This material is available free of charge via the Internet at .http://pubs.acs.org 
Abbreviation
 ITP : inhibition of tubulin polymerization
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Figure 1
Organic curcuminoids and first ferrocenyl curcuminoid derivatives
Figure 2
Percent viability of B16 melanoma cells as a function of the concentration of the organic 3,5-dimethoxycurcumin (circles) or the ferrocenyl3 
analogue (triangles) (48 hour exposure time). Error bars, SD.12 
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Figure 3
Morphological effects of the ferrocenyl curcuminoid . Exponentially growing endothelial cells (EA.hy 926) were exposed to the solvent13 
DMSO at 1  (panel A, control), or to the curcuminoid at a concentration of 6.3 M (panel B), and incubated for 2 h (37 C, 5  CO ).% 13 μ ° % 2 
Representative photographs shown were recorded at an original magnification of 200 X.
Scheme 1
Synthesis of ferrocenyl propenone curcuminoids (series A)
Scheme 2
Synthesis of ferrocenyl methylene curcuminoids (series B)
Scheme 3
Synthesis of ferrocenyl ethanone curcuminoids (series C)
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Table 1
Cytotoxicity, inhibition of tubulin polymerization, and morphological effects on endothelial cells of ferrocenyl curcuminoid derivatives.
Series Compound
Cytotoxicitya Cytotoxicitya
ITPb
Morphological activity on endothelial cells ( M)cμB16 melanoma cells NIH 3T3normal cells
IC ( M)50 μ IC ( M)50 μ IC ( M)50 μ
Organic
(Curcumin)1 8.5 12.3 17.9 50
(Dimethyl-curcumin)2 8.6 19.5 >30 100
3 12.0 27.5 >30 50
4 2.8 15.5 >30 100
Ferrocenyl Unsymmetrical 6 >100 >100 >30 50
7 28.6 56.2 9.3 50
Ferrocenyl Symmetrical A
5 >100 >100 5.8 12.5
8 30.5 >100 2.5 12.5
9 19.0 >100 2.1 12.5
Ferrocenyl Symmetrical B
10 4.2 6.9 21.4 12.5
11 7.1 8.5 3.6 50
12 5.0 24.5 11.0 50
13 2.2 6.2 12.6 6.3
Ferrocenyl Symmetrical C 15
6.9 18.2 5.5 25
17 75.7 4.2 9.9 25
Reference Combreta-statin A4 0.003 0.03 0.26 0.005
a Cytotoxicity on murine B16 melanoma cells or normal NIH 3T3 cells after a 48 hour exposure time. Results are expressed as the concentration that causes 50  cell kill (IC ). Values are the mean of 3% 50 
determinations.
b Inhibition of tubulin polymerization (ITP). Above a threshold value of 30 M, the half maximal inhibitory concentrations (IC ) were not precisely determined.μ 50 
c The lowest active concentration that causes a rounding up of immortalized HUVEC (EA.hy 926) after a 2 hour exposure time.
